We propose a framework to enable quantitative prediction of the impact of CYP2D6
polymorphisms on drug exposure. It relies mostly on in vivo data and uses two characteristic …

We present a unified quantitative approach to predict the in vivo alteration in drug exposure
caused by either cytochrome P450 (CYP) gene polymorphisms or CYP-mediated drug–drug …

Abstract Background and Objective Cytochrome P450 (CYP) 2C9 is the most common
CYP2C enzyme and makes up approximately onethird of total CYP protein content in the …

Purpose: Owing to its highly polymorphic nature and major contribution to the metabolism
and bioactivation of numerous clinically used drugs, CYP2D6 is one of the most extensively …

Abstract Cytochrome P450 2D6 (CYP2D6) is an important drug‐metabolizing enzyme
exhibiting extensive interindividual variability predominantly caused by genetic …

Interindividual variability in drug response depends on a number of genetic and
environmental factors. The metabolic enzymes are well known for their contribution to this …

rs5758550 has been associated with enhanced transcription and suggested to be a useful
marker of CYP2D6 activity. As there are limited and inconsistent data regarding the utility of …

Aims A prospectively enrolled patient cohort was used to assess whether the prediction of
CYP2D6 phenotype activity from genotype data could be improved by reclassification of …

We investigated whether CYP2D6 extensive metabolizers carrying a nonfunctional allele
are at higher risk of phenoconversion to poor metabolizers in the presence of CYP2D6 …

Editorial Leeder & Gaedigk phenotype for allelic variation in CYP2D6 and other CYP genes.
However, we often fail to properly consider some of the nuances associated with …